Sage burns Parkinson's bridge, flunking first of 4 midphase tests for key prospect
Fierce Biotech - 2024-04-17T12:34:00.000Z

Sage Therapeutics has set a bad PRECEDENT for dalzanemdor. | Sage Therapeutics has set a bad PRECEDENT for dalzanemdor. The therapy failed to improve cognitive ability in a phase 2 Parkinson’s disease study, setting Sage off on the wrong foot at the start of a sequence of readouts that will define the future of the molecule. Read this story